Home» Medical News

The FDA has approved Tekamlo

Views: 127
Date: 03 Sep 2010
In pharmacy, a medication, usually mixed with a binder powder, molded and pressed into the form of a tablet,
Something that reduces high blood pressure (hypertension).
The FDA has approved Tekamlo (aliskiren and amlodipine tablets, from Novartis), a single, combination therapy tablet for the treatment of hypertension, alone or with other antihypertensive agents.

Definition of medical terminology for Patients.
Definition of medical terminology for Drugs.
Definition of medical terminology for Blood Pressure.
Definition of medical terminology for Blood Pressure.
Definition of medical terminology for Patients.
Definition of medical terminology for Hypertension.
Definition of medical terminology for Blood Pressure.
In pharmacy, a medication, usually mixed with a binder powder, molded and pressed into the form of a tablet,

Tekamlo is approved as initial therapy for patients who are likely to need multiple drugs to achieve their blood pressure goals, and as replacement therapy when blood pressure is not adequately controlled with either aliskiren or amlodipine alone. This approval was based on clinical trial data from an eight-week, randomized, double-blind, placebo-controlled, multi-factorial study involving more than 5,000 patients with mild-to-moderate hypertension which showed that the combination of Tekturna (aliskiren, from Novartis) and amlodipine resulted in decreases in systolic/diastolic blood pressure at trough of 14a€“17/9a€“11mmHg, compared to 4a€“9/3a€“4mmHg for Tekturna alone, and 9a€“14/6a€“8mmHg for amlodipine alone.

Tekamlo is expected to be available in September 2010 as a once-daily tablet containing aliskiren and amlodipine in 150mg/5mg, 150mg/10mg, 300mg/5mg, and 300mg/10mg dosage strengths.


Source : DrugsFreeList.com
Tags: Tekamlo

Latest Medical News

» U.S. Food And Drug Administration Approves Pfizer’s INLYTA (axitinib) For Patients With Previously Treated Advanced Renal Cell Carcinoma (RCC)
-Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) has approved INLYTA® (axitinib), a kinase inhibitor, for the treatment of patients with advanced renal cell carcinoma (RCC)


» Pfizer Announces FDA Acceptance Of New Drug Application For Bosutinib For Patients With Previously Treated Ph Chronic Myeloid Leukemia
Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for standard review of bosutinib as a treatment option for adult patients with previously treated Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML).


» FDA approves Inlyta to treat patients with a type of advanced kidney cancer
The U.S. Food and Drug Administration approved Inlyta (axitinib) to treat patients with advanced kidney cancer (renal cell carcinoma) who have not responded to another drug for this type of cancer.


» FDA Drug Safety Communication: New risk factor for Progressive Multifocal Leukoencephalopathy (PML) associated with Tysabri (natalizumab)
The U.S. Food and Drug Administration (FDA) is informing the public that testing positive for anti-JC virus (JCV) antibodies has been identified as a risk factor for progressive multifocal leukoencephalopathy (PML).


» FDA. New and Generic Drug Approvals - January 27, 2012
New drugs approved. List of drugs approved by FDA to date January 27, 2012


» FDA. New and Generic Drug Approvals - January 26, 2012
New drugs approved. List of drugs approved by FDA to date January 26, 2012


» FDA. New and Generic Drug Approvals - January 25, 2012
New drugs approved.List of drugs approved by FDA to date January 25, 2012


» FDA. New and Generic Drug Approvals - January 24, 2012
New drugs approved. List of drugs approved by FDA to date January 24, 2012


» FDA. New and Generic Drug Approvals - January 23, 2012
New drugs approved.List of drugs approved by FDA to date January 23, 2012


» FDA. New and Generic Drug Approvals - January 20, 2012
New drugs approved. List of drugs approved by FDA to date January 20, 2012


» FDA. New and Generic Drug Approvals - January 19, 2012
New drugs approved. List of drugs approved by FDA to date January 19, 2012


» FDA. New and Generic Drug Approvals - January 18, 2012
New drugs approved. List of drugs approved by FDA to date January 18, 2012


» FDA expands use of endovascular graft to treat aortic tears
The U.S. Food and Drug Administration expanded the approved usage for an endovascular graft manufactured by W.L. Gore and Associates Inc. to include treatment of life-threatening tears or ruptures of the aorta (thoracic aortic transection).


» FDA approves Voraxaze to treat patients with toxic methotrexate levels
The U.S. Food and Drug Administration approved Voraxaze (glucarpidase) to treat patients with toxic levels of methotrexate in their blood due to kidney failure.


» FDA Drug Safety Communication: New Boxed Warning and Contraindication for Adcetris (brentuximab vedotin)
The U.S. Food and Drug Administration (FDA) is notifying the public that two additional cases of progressive multifocal leukoencephalopathy (PML), a rare but serious brain infection that can result in death, have been reported with the lymphoma drug Adcetris (brentuximab vedotin).


General Search


Last medical tags:


Torisel, temsirolimus, Inlyta, chronic myeloid leukemia, bosutinib, Inlyta, renal cell carcinoma, kidney cancer, myelin, Tysabri, natalizumab, brain infection, progressive multifocal leukoencephalopathy, FDA, New drugs approval 2012, drugs approved by FDA, FDA, New drugs approval 2012, drugs approved by FDA, FDA, New drugs approval 2012, drugs approved by FDA, FDA, New drugs approval 2012, drugs approved by FDA, FDA, New drugs approval 2012, drugs approved by FDA, FDA, New drugs approval 2012, drugs approved by FDA, FDA, New drugs approval 2012, drugs approved by FDA, FDA, New drugs approval 2012, drugs approved by FDA, thoracic aortic transection, endovascular graft, methotrexate, Voraxaze, cancer chemotherapy drug, glucarpidase, Adcetris, bleomycin, multifocal leukoencephalopathy, CardioGen-82, radiation, FDA, New drugs approval 2012, drugs approved by FDA, FDA, New drugs approval 2012, drugs approved by FDA, FDA, New drugs approval 2012, drugs approved by FDA, raltegravir, Isentress, antiretroviral medicines, Theravance, Relovair, asthma, fluticasone, bronchitis, neuromuscular disease, SMA, muscle atrophy, Resolor, prokinetic, prucalopride, ADHD, psychiatric behavioural disorder, Venvanse, lisdexamfetamine dimesylate, type 2 diabetes mellitus, Actoplus Met XR, pioglitazone, Mylan, Eprosartan Mesylate Tablets, Teveten, antimicrobials, cephapirin, cephalosporin, teriflunomide, Rebif, alanine aminotransferase levels, flu-like symptoms, multiple sclerosis, electrical pulses, implantable pulse generator, Precision Plus Spinal Cord Stimulator, genetic blood clotting disorder, hemophilia A, Advate, bleeding episodes, heart failure, heart transplantation, Pediatric Medical Device Safety, pulsatile cardiac assist device, selective serotonin reuptake inhibitor, SSRI, pulmonary hypertension,
» All tags  
Sitemap